Today's Rundown Featured Story | | | Tuesday, July 24, 2018 Biogen has bolted on a couple of early-stage drug candidates for neuromuscular diseases via a $535 million deal with California startup AliveGen. |
|
|
| This week's sponsor is FierceBiotech. | |  | |
Top Stories Tuesday, July 24, 2018 Merck has posted 96-week data on an HIV prospect it hopes will replace drugs including Bristol-Myers Squibb’s Sustiva in combination regimens. The update linked Merck’s doravirine to a higher rate of viral suppression than a combination of antiretroviral drugs from AbbVie and Johnson & Johnson. Tuesday, July 24, 2018 Bristol-Myers Squibb has teamed up with China’s Tsinghua University to discover drugs that hit novel cancer and autoimmune disease targets. The agreement tasks Tsinghua with discovering therapeutics that Bristol-Myers can then choose to license. Monday, July 23, 2018 Gene and cell therapies are at the cutting-edge of biomedical research, promising potentially curative options for a host of disorders such as forms of blindness, blood cancers and inherited diseases. Monday, July 23, 2018 Gossamer Bio netted $230 million in a series B financing round—on the heels of its $100 million launch in January—to accelerate the company’s growth and fund clinical trials of candidates with undisclosed targets in immunology, inflammation, immuno-oncology and fibrosis. Monday, July 23, 2018 Roivant Sciences’ rare disease offshoot, Enzyvant, is partnering up with PerkinElmer Genomics to develop a test for the genetic mutations associated with Farber disease, an ultrarare lysosomal storage disorder. Tuesday, July 24, 2018 Synexus, a global site management organization, is partnering with the University of Exeter in the U.K. to launch a registry-based study in the U.S. to better understand how healthy brains age. | This week's sponsor is IQVIA. | |  | |
Resources Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Medidata Accelerate Clinical Research as Study Complexity Grows Sponsored by: Patheon, part of Thermo Fisher Scientific Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy. Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online The Life Science Women's Conference August 8-9, 2018 | Austin, Texas Join 200+ Service and Support Leaders at Field Service Amelia Island this August August 27-29, 2018 | Amelia Island, FL BIO Latin America 2018 September 4-5, 2018 | São Paulo, Brazil RESI HealthTech Week September 5-7, 2018 | Boston, MA 2018 Latin America Healthcare Compliance Certification Program Sao Paulo, Brazil | Sep 24-27, 2018 4th Annual Bio/Pharmaceutical Product Launch Summit September 25-26, 2018 | Cambridge, MA Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA The Advanced Biologic Development Summit at Northeastern University October 9, 2018 | Boston, MA BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation | 
